Callitas Theraputics Inc., a wholly owned subsidiary of Callitas Health Inc.

Callitas Health Accelerates Commercial Licensing and Engages Feyeur and Trogue, a Speciality Healthcare Consulting Firm


CINCINNATI, OH, USA (January 22, 2018) – Callitas Health Inc. (CSE: LILY, OTCBB: MPHMF, FWB: T3F2), (the “Company” or “Callitas”) a clinical-stage company developing innovative technologies for weight management and female health and wellness, today announced that Freyeur & Trogue (“F&T”), of New York, New York, has been engaged by Callitas to provide management and business development consulting services to help optimize Callitas’ product portfolio development and commercialization.

F&T is a specialty consulting and investment banking firm that provides a unique combination of advisory and consulting services to help life science and technology companies realize their growth potential. F&T helps clients identify and exploit new businesses, new markets, new products and new brands to create value for their company.

“We are excited about partnering with Freyeur & Trogue to advance our commercial development, licensing and strategic partnering strategies in the US and multiple international markets, where discussions with potential partners have already begun,” says James Thompson, Interim President & CEO. “Freyeur & Trogue bring decades of pharmaceutical development, partnering and fundraising expertise to help us accelerate our business.”

Engaging F&T underscores Callitas’ commitment to bring innovative and uniquely beneficial weight management and female health and wellness products to patients with unmet or underserved health care needs.

About Callitas Health

Formed in early 2015, Callitas Health Inc. is a clinical-stage company developing innovative technologies for obesity, weight management and female health & wellness. In addition to its recent acquisitions of C-103, a reformulation of Orlistat, Extrinsa and assets from 40J’s LLC, the Company successfully launched ToConceive in North America as a clinically proven option for couples struggling with the inability to conceive.

Callitas Health Inc. trades on the Canadian Securities Exchange (CSE) under the ticker symbol “LILY” as well as on the OTCQB as “MPHMF” and FWB (Frankfurt Stock Exchange) as “T3F2.”

For more information contact:

James Thompson, CEO, or
Callitas Investor Relations
Phone: +1 (859) 868-3131

Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the regulatory approval and the commercialization of the rights to the Company’s biomedical & drug technologies.  Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on and the Company’s filings to the CSE at  Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.

Notice regarding investigational devices:  CannaMint Strips, C-103 and Extrinsa are investigational drugs or devices and are not currently available outside of approved clinical trials.  Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body.

Neither the Canadian Securities Exchange nor its Regulation Service Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.


As a company, our number one goal is helping people by bringing products to market that improve quality of life. All our drug treatments and biomedical technologies fit our mission to deliver breakthrough products and services that reduce invasiveness and enhance daily living.


  • 1.859.868.3131

  • 187 Pavilion Parkway
    Suite 200
    Newport, Kentucky 41071